IDEXX Laboratories, Inc. $IDXX Stock: Rakuten Investment Management Inc. Boosts Holdings

Rakuten Investment Management Inc. lifted its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 10.2% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 20,981 shares of the company’s stock after acquiring an additional 1,945 shares during the period. Rakuten Investment Management Inc.’s holdings in IDEXX Laboratories were worth $11,192,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently modified their holdings of the company. Aurora Investment Managers LLC. purchased a new stake in shares of IDEXX Laboratories in the second quarter worth about $2,442,000. National Pension Service grew its position in IDEXX Laboratories by 5.6% during the second quarter. National Pension Service now owns 129,305 shares of the company’s stock valued at $68,071,000 after buying an additional 6,885 shares during the period. NewEdge Advisors LLC boosted its position in IDEXX Laboratories by 60.9% during the first quarter. NewEdge Advisors LLC now owns 15,221 shares of the company’s stock worth $8,552,000 after purchasing an additional 5,761 shares in the last quarter. Arizona State Retirement System grew its holdings in IDEXX Laboratories by 4.9% in the second quarter. Arizona State Retirement System now owns 22,772 shares of the company’s stock valued at $11,988,000 after purchasing an additional 1,074 shares during the period. Finally, Howard Capital Management LLC purchased a new position in shares of IDEXX Laboratories during the 3rd quarter valued at approximately $1,249,000. 87.84% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of analysts have recently commented on the stock. Jefferies Financial Group cut their target price on shares of IDEXX Laboratories from $795.00 to $705.00 and set a “buy” rating for the company in a research note on Tuesday, October 20th. Barclays lowered their price target on IDEXX Laboratories from $800.00 to $710.00 and set an “overweight” rating on the stock in a research note on Tuesday, August 11th. Citigroup raised their price target on shares of IDEXX Laboratories from $650.00 to $670.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 5th. Weiss Ratings upgraded shares of IDEXX Laboratories from a “hold (c)” rating to a “hold (c+)” rating in a report on Thursday, October 8th. Finally, Morgan Stanley increased their price target on IDEXX Laboratories from $805.00 to $810.00 and gave the company an “overweight” rating in a report on Tuesday. Seven analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $719.55.

IDEXX Laboratories Stock Up 3.9%

Shares of IDXX opened at $698.55 on Thursday. The company’s 50-day simple moving average is $541.78 and its 200-day simple moving average is $573.62. The company has a debt-to-equity ratio of 0.16, a quick ratio of 0.87 and a current ratio of 1.19. IDEXX Laboratories, Inc. has a 1 year low of $500.61 and a 1 year high of $769.98. The stock has a market capitalization of $55.04 billion, a PE ratio of 45.41 and a beta of 1.55.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings data on Monday, November 2nd. The company reported $3.96 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.71 by $0.25. IDEXX Laboratories had a return on equity of 71.04% and a net margin of 25.36%. The business had revenue of $1.21 billion during the quarter, compared to analysts’ expectations of $1.19 billion. During the same quarter last year, the business posted $3.22 EPS. The business’s quarterly revenue was up 9.9% compared to the same quarter last year. Analysts forecast that IDEXX Laboratories, Inc. will post 15.06 earnings per share for the current fiscal year.

Key Headlines Impacting IDEXX Laboratories

Here are the key news stories impacting IDEXX Laboratories this week:

• Positive Sentiment: IDEXX reported Q3 adjusted EPS of $3.96, above the $3.71 consensus, and revenue of $1.21 billion, ahead of expectations. The company also raised its FY2026 EPS guidance to $14.96–$15.16, versus analysts’ prior $14.86 estimate; its $4.7–$4.8 billion revenue outlook is broadly in line with consensus. IDEXX Q3 beat and raised outlook
• Positive Sentiment: UBS said the company delivered strong results despite a lackluster veterinary-visit backdrop, suggesting execution and demand for its offerings remain resilient. UBS comments on IDEXX results
• Positive Sentiment: Morgan Stanley maintained an overweight rating and raised its price target to $810, signaling continued analyst confidence in the shares.
• Neutral Sentiment: One Seeking Alpha analysis characterized IDEXX’s Q3 performance as best-in-class, while another downgraded the stock, arguing that its valuation is too high. The mixed assessments leave valuation as a key consideration after the rally. Valuation-focused downgrade

Insider Buying and Selling

In other news, Director Lawrence D. Kingsley sold 2,203 shares of IDEXX Laboratories stock in a transaction dated Friday, September 4th. The stock was sold at an average price of $532.08, for a total transaction of $1,172,172.24. Following the sale, the director owned 9,568 shares in the company, valued at approximately $5,090,941.44. The trade was a 18.72% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 0.79% of the stock is owned by corporate insiders.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) develops and provides diagnostic, information technology, and related products and services for the animal health and water testing markets. The company primarily serves veterinary practices, helping them diagnose and monitor diseases through laboratory tests, in-clinic analyzers, software, and digital practice-management solutions.

IDEXX’s companion animal offerings include hematology, chemistry, urinalysis, immunodiagnostics, and imaging-related products, along with reference laboratory services and veterinary software.